Chemistry:Elzasonan

From HandWiki
Short description: Chemical compound
Elzasonan
Elzasonan structure.svg
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC22H23Cl2N3OS
Molar mass448.41 g·mol−1
3D model (JSmol)
  (verify)

Elzasonan (CP-448,187) is a selective 5-HT1B and 5-HT1D receptor antagonist that was under development by Pfizer for the treatment of depression but was discontinued, possibly due to poor efficacy.[1][2][3][4][5] By preferentially blocking 5-HT1B and 5-HT1D autoreceptors, elzasonan is thought to enhance serotonergic innervations originating from the raphe nucleus, thereby improving signaling to limbic regions like the hippocampus and prefrontal cortex and ultimately resulting in antidepressant effects.[3]

See also

References

  1. Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. 2007. ISBN 978-3-527-31058-6. https://books.google.com/books?id=yXD4QA-Y_Z0C&pg=PA255. 
  2. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge, UK: Cambridge University Press. 2008. ISBN 978-0-521-85702-4. https://books.google.com/books?id=cWbYxSfKN3cC&q=Elzasonan&pg=PA659. 
  3. 3.0 3.1 "5-HT1 receptor augmentation strategies as enhanced efficacy: therapeutics for psychiatric disorders". Current Topics in Medicinal Chemistry 8 (12): 1008–1023. August 2008. doi:10.2174/156802608785161439. PMID 18691129. 
  4. "Pfizer, Inc.: analysis of patenting 1998 – 2001". Expert Opinion on Therapeutic Patents 12 (5): 725–732. 2002. doi:10.1517/13543776.12.5.725. 
  5. "Discontinued psychiatric drugs in 2008". Expert Opinion on Investigational Drugs 18 (10): 1431–1443. October 2009. doi:10.1517/13543780903184591. PMID 19715445.